Tag
A recent randomized clinical trial demonstrates amiloride’s noninferiority to spironolactone in lowering systolic blood pressure in resistant hypertension, offering a promising alternative therapy.
This analysis of the TOPCAT trial cohort evaluates the association between β-blocker use and health status in HFpEF patients, revealing no significant impact on baseline quality of life or modification of spironolactone benefits.
This review consolidates evidence from the ACHIEVE trial and related studies evaluating spironolactone’s efficacy and safety in patients undergoing maintenance dialysis, highlighting lack of cardiovascular benefit and discussing futur
The ALCHEMIST trial reveals spironolactone does not improve cardiovascular outcomes in high-risk chronic haemodialysis patients, aligning with a meta-analysis that challenges the benefit of mineralocorticoid receptor antagonists in this pop
The SOGALDI-PEF trial evaluates the effects of dapagliflozin combined with spironolactone versus dapagliflozin alone in patients with heart failure, revealing significant improvements in NT-proBNP levels and safety concerns.
